Favorable early-stage Hodgkin lymphoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 3, 2006, Pages 233-240

  Yahalom, Joachim ^a,b,c  

^a Weill Medical College of Cornell University ^*

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer staging; Chemotherapy; Favorable early stage disease; Hodgkin lymphoma; Involved field radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FOLLOW UP; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; LAPAROTOMY; LUNG TOXICITY; LYMPH NODE IRRADIATION; MIXED CELLULARITY HODGKIN LYMPHOMA; MULTIMODALITY CANCER THERAPY; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PROGNOSIS; RADIATION; RADIATION DOSE; REVIEW; RISK FACTOR; SURVIVAL RATE; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; PATHOLOGY; RADIOTHERAPY; SURVIVAL;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; RADIOTHERAPY; SURVIVAL ANALYSIS;

EID: 33645942420     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0022     Document Type: Review

References (47)

1. DeVita VT Jr. Hodgkin's disease: clinical trials and travails. N Engl J Med 2003;348:2375-2376.
2. Longo DL. Radiation therapy in the treatment of Hodgkin's disease: do you see what I see? J Natl Cancer Inst 2003;95:928-929.
3. Longo DL. Hodgkin disease: the sword of Damocles resheathed. Blood 2003;104:3418.
4. Longo DL. Radiation therapy in Hodgkin disease: why risk a Pyrrhic victory? J Natl Cancer Inst 2005;97:1394-1395.
5. Canellos GP. Chemotherapy alone for early Hodgkin's lymphoma: an emerging option. J Clin Oncol 2005;23:4574-4576.
6. Yahalom J. Breast cancer after Hodgkin disease: hope for a safer cure. JAMA 2003;290:529-531.
7. Yahalom J. "Don't throw out the baby with the bathwater." On optimizing cure and reducing toxicity in Hodgkin lymphoma. J Clin Oncol (in press).
8. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-1636.
9. Specht L, Gray RG, Clarke MJ, et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998;16:830-843.
10. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma: diagnosis and treatment. Lancet Oncol 2004;5:19-26.
11. Hoppe RT, Advani RH, Bierman PJ, et al. NCCN Hodgkin disease clinical practice guidelines in oncology, 2006 v.1. Available at: http://www.nccn.org. Last accessed January 6, 2006.
12. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002;20:2101-2108.
13. Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002;100:989-996.
14. Sieber M, Franklin J, Tesch H, et al. Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease: results of the German Hodgkin's Lymphoma Study Group (GHSG) Trial HD7 [abstract]. Blood 2002;100:A341.
15. Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001;19:4238-4244.
16. Carde P, Noordijk E, Hagenbeek A. Superiority of EBVP chemotherapy in combination with involved field irradiation over subtotal nodal irradiation in favorable clinical stage I-II Hodgkin's disease: the EORTC-GPMC H7F randomized trial. Proc ASCO 1997;16:13.
17. Hagenbeek A, Eghbali H, Ferme C, et al. Three cycles of MOPP/ABV hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favorable supradiaphragmatic clinical stages 1-11 Hodgkin's disease: preliminary results of the EORTC-GELA H9-F randomized trial in 543 patients [abstract]. Blood 2000;96:A575.
18. Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004;22:2835-2841.
19. Ferme C, Eghbali H, Hagenbeek A, et al. MOPP/ABV hybrid and irradiation in unfavorable supradiaphragmatic clinical stages I-II Hodgkin's disease: comparison of three treatment modalities. Preliminary results of the EORTC-GELA H8-U randomized trial in 995 patients [abstract]. Blood 2000;96:A576.
20. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:3601-3608.
21. Loeffler M, Diehl V, Pfreundschuh M, et al. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. J Clin Oncol 1997;15:2275-2287.
22. Diehl V, Brillant C, Engert A, et al. HD10: investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG) [abstract]. J Clin Oncol 2005;21(suppl 1):abstract #6506.
23. Diehl V, Brillant C, Engert A, et al. Recent interim analysis of the HD11 trial of the GHSG: Intensification of chemotherapy and reduction of radiation dose in early unfavorable stage Hodgkin's lymphoma [abstract]. Blood 2005;106:abstract #816.
24. Noordijk E, Thomas J, Ferme C, et al. First results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL) [abstract]. J Clin Oncol 2005;21(supp 1): abstract #6506.
25. Eghbali H, Brice P, Creemers G, et al. Comparison of three radiation dose levels after EBVP regimen in favorable subdiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma: Preliminary results of the EORTC/GELA H9-F trial [abstract]. Blood 2005;106: abstract #814.
26. Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002;13(suppl 1):79-83.
27. Goodman KA, Toner S, Hunt M, et al. Intensity modulated radiation therapy in the treatment of lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 2005;62:198-206.
28. Girinsky T, Pichenot C, Beaudre A, et al. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for heam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 2006;64:218-226.
29. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-192.
30. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003;95:971-980.
31. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465-475.
32. Kuttesch JF Jr, Wexler LH, Marcus RB, et al. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol 1996;14:2818-2825.
33. Koontz B, Kirkpatrick J, Clough R, et al. Combined modality therapy versus radiotherapy alone for treatment of early stage Hodgkin disease: cure versus complications. J Clin Oncol (in press).
34. Salloum E, Doria R, Schubert W, et al. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 1996;14:2435-2443.
35. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004;22:62-68.
36. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634-4642.
37. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104:3483-3489.
38. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002;20:3765-3771.
39. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999;17:776-783.
40. Schlembach PJ, Wilder RB, Jones D, et al. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J 2002;8:377-383.
41. Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 2005;104:1221-1229.
42. Wilder RB, Schlembach PJ, Jones D, et al. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer 2002;94:1731-1738.
43. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003;101:4285-4289.
44. Murphy SB, Morgan ER, Katzenstein HM, et al. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol 2003;25:684-687.
45. Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte- predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection: a Study of the French Society of Pediatric Oncology European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. J Clin Oncol 2003;21:2948-2952.
46. Lavely WC, Delbeke D, Greer JP, et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys 2003;57:307-315.
47. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21:3431-3439.